Patent intelligence · US
US 9890210
Antagonist antibodies directed against calcitonin gene-related peptide
Antagonist antibodies directed against calcitonin gene-related peptide
Patent details — US 9890210
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 13, 2018
- Expiration
- Feb 8, 2038
- Applicant
- TEVA PHARMACEUTICALS INTERNATIONAL GMBH
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61K31/4045, A61K39/3955
Quick answer
US 9890210 (Antagonist antibodies directed against calcitonin gene-related peptide) is held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH. Status: granted. Granted Feb 13, 2018. Expires Feb 8, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA PHARMACEUTICALS INTERNATIONAL GMBH
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61K31/4045, A61K39/3955, A61P, A61P25/00
More from TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 9890210?
US 9890210 (Antagonist antibodies directed against calcitonin gene-related peptide) is held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH. Status: granted. Granted Feb 13, 2018. Expires Feb 8, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9890210?
TEVA PHARMACEUTICALS INTERNATIONAL GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 9890210 expire?
Our index shows an expiration date of Feb 8, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.